SG Americas Securities LLC Makes New Investment in Integra LifeSciences Holdings Corporation $IART

SG Americas Securities LLC bought a new position in Integra LifeSciences Holdings Corporation (NASDAQ:IART) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 380,229 shares of the life sciences company’s stock, valued at approximately $4,722,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rubric Capital Management LP boosted its holdings in Integra LifeSciences by 58.4% in the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock worth $90,233,000 after purchasing an additional 2,710,262 shares during the period. Paradigm Capital Management Inc. NY raised its holdings in shares of Integra LifeSciences by 57.5% during the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock worth $26,767,000 after purchasing an additional 796,300 shares during the period. Soleus Capital Management L.P. lifted its position in shares of Integra LifeSciences by 29.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 1,387,818 shares of the life sciences company’s stock worth $17,029,000 after buying an additional 315,614 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Integra LifeSciences by 9.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock worth $45,634,000 after buying an additional 267,134 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Integra LifeSciences in the 2nd quarter valued at about $2,960,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on IART. Wells Fargo & Company upgraded shares of Integra LifeSciences to a “hold” rating in a research note on Wednesday, March 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a report on Friday, March 27th. Wall Street Zen cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Citigroup reduced their price objective on Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating for the company in a research report on Wednesday, March 11th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Integra LifeSciences has a consensus rating of “Reduce” and an average target price of $14.40.

Integra LifeSciences Price Performance

NASDAQ IART opened at $9.57 on Thursday. The company has a 50-day moving average price of $10.50 and a two-hundred day moving average price of $12.33. Integra LifeSciences Holdings Corporation has a 52 week low of $8.70 and a 52 week high of $21.88. The stock has a market cap of $745.89 million, a price-to-earnings ratio of -1.42 and a beta of 1.06. The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The business had revenue of $434.93 million during the quarter, compared to the consensus estimate of $429.62 million. During the same period in the previous year, the firm posted $0.97 earnings per share. The business’s revenue was down 1.7% on a year-over-year basis. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.